Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Senate Wants Priority Review For 'Deemed' Biologics Not Approved By Deadline

Sep 20 2019

• By Derrick Gingery

FDA entrance sign 2016 — The 2020 transition for insulin and other products from drug to biologics regulation still worries legislators and others. • Source: Shutterstock

Related Content

US FDA's New Drug Assessors More Experienced With Rare Disease Issues

Sep 11 2019

Mylan/Biocon Running Out Of Time To Get Insulin Approved Before US Transition

Sep 05 2019

House Appropriators Tip-Toe Into Biologics Transition Controversy

Jun 04 2019

Biologics Transition 'Dead Zone' Could Be Eliminated Under US Senate Bill

May 28 2019

US FDA Gets Another Appropriations Increase In FY 2020 House Bill

May 22 2019

A Guide To US FDA’s Drug-To-Biologic Transition Process

May 09 2019

US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews

Oct 29 2018

Insulin Applications Intended For Biosimilar Pathway May Already Be At US FDA

Apr 02 2019

Related Companies

Sanofi

Viatris Inc.

Biocon, Ltd.

Additional Topics

United States Biologics Legislation Review Pathway Regulation Drug Review FDA Rare Diseases BioPharmaceutical

More from Legislation

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window